We are monitoring the impact of COVID-19 on Europe Cardiovascular Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date November, 2021
ID: 12442
Share on
Share on

Europe Cardiovascular Drugs Market Research Report – Segmented By Drugs Type, Disease indication, End-Users and Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: November, 2021
ID: 12442
Pages: 100

Europe Cardiovascular Drugs Market Size (2021 to 2026)

The size of the cardiovascular drugs market in the European region is forecasted to grow USD 36.19 billion by 2026 from USD 28.16 billion in 2021, growing at a CAGR of 5.15% from 2021 to 2026.

Y-O-Y growth in the prevalence of cardiovascular diseases and the growing geriatric population are primarily expected to boost the European cardiovascular drugs market. Other factors influencing the market growth include constant changes in lifestyle, unhealthy eating habits, inactivity of the body, obesity, and smoking; these factors increase the risk of cardiovascular disease, so the prevalence of chronic disease is rising. In addition, increasing competition between the market players for introducing effective products in the market is enabling the market players to implement market strategies to gain a competitive advantage over the marketplace. The market strategies include mergers, acquisitions, and partnerships.  The increasing demand for effective drugs and therapy is also expected to favor the market growth in this region. 

On the other hand, the rising research and development activities, growing healthcare spending, and favorable reimbursement policies boost the market growth. Moreover, key market players in the region are focussing on the adoption and launch of a new products, and therapies which are expected to provide lucrative growth opportunities to the market growth. Furthermore, increase in the investments and fundings from government and non-government organizations in research and development activities for manufacturing new and effective drugs for heart disease. Also, the initiatives for developing proper medical and healthcare infrastructure propel the growth of the cardiovascular drugs market in this region.

However, stringent government rules and regulations are majorly restraining the market growth. Additionally, the high cost of treatment and drug production, the patent expiration of many pharmaceuticals, which causes numerous generic copies of drugs to reach the market, hinder the growth of cardiovascular drugs. In addition, the strict approval process for approving new products or drugs into the market and side effects and allergies related to the drugs such as diarrhea, low blood pressure, and other effects. Furthermore, the lack of proper medical and health care services also is expected to limit the market growth of the European cardiovascular drugs market.

This research report on the European cardiovascular drugs market has been segmented and sub-segmented into the following categories.

By Drug Type:

  • Antihypertensive
  • Antihyperlipidemic
  • Anticoagulants
  • Antiplatelet Drugs
  • Others

By Disease Indication:

  • Hypertension
  • Hyperlipidemia
  • Coronary Artery Disease
  • Arrhythmia
  • Others

By End-Users:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Geographically, the European market is the second-largest market in the global cardiovascular drugs market and is predicted to be growing at a healthy growth rate during the forecast period. The market in this region is attributed to the availability of advanced healthcare infrastructure, high healthcare spending, and favorable reimbursement policies. In addition, an increase in the growing population with the rising old age population is majorly driving the market growth. Also, there is an increase in the prevalence of rising chronic diseases such as cardiovascular diseases, including heart attacks, vascular dementia, strokes, coronary artery disease, blood clots, and many more. As a result, in this region, there are more than 6 million new rising cases of cardiovascular disease in the EU. As a result, there are more than 11 million cases in Europe, increasing the demand for cardiovascular drugs in the market.

Cardiovascular disease is common among the countries in this region, such as the UK, Germany, Italy, France, and Spain, and is the leading cause of death among all ages. The major contributors in the region are Germany, France, the UK, Spain, and Italy.

Germany led the European cardiovascular drugs market in 2020, and it is anticipated to register significant growth during the forecast period. Rising prevalence of chronic diseases, a substantial increase in investments and fundings from government and non-government organizations in research and development activities and

Similarly, the UK is most likely to witness a considerable share in the European cardiovascular drugs market during the forecast period. Growing awareness among the people, rising senior population, and sedentary lifestyles are propelling the market growth. Also, the initiatives for developing proper medical and healthcare infrastructure drive the market growth.

KEY MARKET PLAYERS:

Companies playing a prominent role in the EU cardiovascular drugs market profiled in this report are Merck & Co, Sanofi S.A., Pfizer Inc., Bristol-Myers Squibb Company, and Novartis AG.

1. Introduction                                   

            1.1 Market Definition            

            1.2 Scope of the report                     

            1.3 Study Assumptions                      

            1.4 Base Currency, Base Year and Forecast Periods             

2. Research Methodology                             

            2.1 Analysis Design                

            2.2 Research Phases              

                        2.2.1 Secondary Research     

                        2.2.2 Primary Research          

                        2.2.3 Data Modelling 

                        2.2.4 Expert Validation          

            2.3 Study Timeline                 

3. Report Overview                            

            3.1 Executive Summary                     

            3.2 Key Inferences                 

4. Market Dynamics                           

            4.1 Impact Analysis                

                        4.1.1 Drivers  

                        4.1.2 Restraints          

                        4.1.3 Opportunities   

            4.2 Regulatory Environment              

            4.3 Technology Timeline & Recent Trends                

5. Competitor Benchmarking Analysis                                  

            5.1 Key Player Benchmarking            

                        5.1.1 Market share analysis   

                        5.1.2 Products/Service          

                        5.1.3 Regional Presence        

            5.2 Mergers & Acquisition Landscape                       

            5.3 Joint Ventures & Collaborations              

6. Market Segmentation                                

            6.1 Europe Cardiovascular Drugs Market – By Drug Type:                

                        6.1.1 Antihypertensive         

                        6.1.2 Antihyperlipidemic       

                        6.1.3 Anticoagulants  

                        6.1.4 Antiplatelet Drugs        

                        6.1.5    Others

                        6.1.6 Market Size Estimations & Forecasts (2021-2026)      

                        6.1.7 Y-o-Y Growth Rate Analysis      

                        6.1.8 Market Attractiveness Index    

            6.2 Europe Cardiovascular Drugs Market – By Disease Indication:               

                        6.2.1    Hypertension 

                        6.2.2      Hyperlipidaemia       

                        6.2.3 coronary artery disease           

                        6.2.4 Arrhythmia       

                        6.2.5 Others   

                        6.2.6 Market Size Estimations & Forecasts (2021-2026)      

                        6.2.7 Y-o-Y Growth Rate Analysis      

                        6.2.8 Market Attractiveness Index    

            6.3 Europe Cardiovascular Drugs Market – By End-Users:                

                        6.3.1 Hospital Pharmacies     

                        6.3.2  Retail Pharmacies        

                        6.3.3 Online Pharmacies        

                        6.3.4    Others

                        6.3.5 Market Size Estimations & Forecasts (2021-2026)      

                        6.3.6 Y-o-Y Growth Rate Analysis      

                        6.3.7 Market Attractiveness Index    

7. Geographical Landscape                            

            7.3 Europe                 

                        7.3.1 By Country        

                                    7.3.1.1 UK

                                    7.3.1.2 France

                                    7.3.1.3 Germany

                                    7.3.1.4 Spain

                                    7.3.1.5 Italy

                                    7.3.1.6 Rest of Europe

                        7.3.2 By Drug Type:   

                        7.3.3 By Disease Indication:  

                        7.3.4 By End-Users:    

8. Key Player Analysis                        

            8.1 Merck & Co                      

                        8.1.1 Business Description    

                        8.1.2 Products/Service          

                        8.1.3 Financials          

                        8.1.4 SWOT Analysis  

                        8.1.5 Recent Developments  

                        8.1.6 Analyst Overview          

            8.2 Sanofi S.A.            

            8.3 Pfizer Inc.             

            8.4 Bristol-Myers Squibb Company               

            8.5 Novartis AG                      

9. Market Outlook & Investment Opportunities                               

10.Appendix                           

            List of Tables              

            List of Figures             

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and also identify the areas that are still untapped. 
  • The segment-level analysis in terms of drug type, disease indication, end-users, and region along with market size forecasts and estimations to detect key areas of industry growth in detail.
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.
  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development.
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, essential financial information, legal issues, SWOT analysis, and analyst overview to study and sustain the market environment.
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies, and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions.
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations with a strong financial foothold in the market.
  1. Europe Cardiovascular Drugs Market By Drug Type, From 2021 to 2026 ( USD Billion )
  2. Europe Antihypertensive Market By Region, From 2021 to 2026 ( USD Billion )
  3. Europe Antihyperlipidemic Market By Region, From 2021 to 2026 ( USD Billion )
  4. Europe Anticoagulants Market By Region, From 2021 to 2026 ( USD Billion )
  5. Europe   Antiplatelet Drugs Market By Region, From 2021 to 2026 ( USD Billion )
  6. Europe Others Market By Region, From 2021 to 2026 ( USD Billion )
  7. Europe Cardiovascular Drugs Market By Disease Indication, From 2021 to 2026 ( USD Billion )
  8. Europe Hypertension Market By Region, From 2021 to 2026 ( USD Billion )
  9. Europe Hyperlipidaemia Market By Region, From 2021 to 2026 ( USD Billion )
  10. Europe  Coronary Artery Disease Market By Region, From 2021 to 2026 ( USD Billion )
  11. Europe   Arrhythmia Market By Region, From 2021 to 2026 ( USD Billion )
  12. Europe   Others Market By Region, From 2021 to 2026 ( USD Billion )
  13. Europe Cardiovascular Drugs Market By End-Users, From 2021 to 2026 ( USD Billion )
  14. Europe  Hospital Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )
  15. Europe Retail Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )
  16. Europe    Online Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )
  17. Europe Others Market By Region, From 2021 to 2026 ( USD Billion )
  18. U.K. Cardiovascular Drugs Market By Drug Type, From 2021 to 2026 ( USD Billion )
  19. U.K. Cardiovascular Drugs Market By Disease Indication, From 2021 to 2026 ( USD Billion )
  20. U.K. Cardiovascular Drugs Market By End-Users, From 2021 to 2026 ( USD Billion )
  21. Germany Cardiovascular Drugs Market By Drug Type, From 2021 to 2026 ( USD Billion )
  22. Germany Cardiovascular Drugs Market By Disease Indication, From 2021 to 2026 ( USD Billion )
  23. Germany Cardiovascular Drugs Market By End-Users, From 2021 to 2026 ( USD Billion )
  24. France Cardiovascular Drugs Market By Drug Type, From 2021 to 2026 ( USD Billion )
  25. France Cardiovascular Drugs Market By Disease Indication, From 2021 to 2026 ( USD Billion )
  26. France Cardiovascular Drugs Market By End-Users, From 2021 to 2026 ( USD Billion )
  27. Italy Cardiovascular Drugs Market By Drug Type, From 2021 to 2026 ( USD Billion )
  28. Italy Cardiovascular Drugs Market By Disease Indication, From 2021 to 2026 ( USD Billion )
  29. Italy Cardiovascular Drugs Market By End-Users, From 2021 to 2026 ( USD Billion )
  30. Spain Cardiovascular Drugs Market By Drug Type, From 2021 to 2026 ( USD Billion )
  31. Spain Cardiovascular Drugs Market By Disease Indication, From 2021 to 2026 ( USD Billion )
  32. Spain Cardiovascular Drugs Market By End-Users, From 2021 to 2026 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample